HOME >> BIOLOGY >> NEWS
University of Rochester scientists test new method to attack cancer

NOTE: This release has been updated since its original posting.

Scientists have used a technique called RNA interference to impair cancer cells' ability to produce a key enzyme called telomerase. The enzyme, present in most major types of cancer cells, gives cells the lethal ability to divide rampantly without dying. The laboratory experiments create an opportunity for researchers who are focusing on telomerase in a bid to develop a drug like none ever developed - one capable of killing 85 percent of cancers

The research, led by Peter T. Rowley, M.D., of the University of Rochester Medical Center, is being presented today at the annual meeting of the American Association for Cancer Research in Washington, D.C.

The enzyme telomerase produces telomeres, located at the ends of each chromosome, which protect the ends of chromosomes as cells divide. In a normal cell, the telomeres shorten each time the cell divides. After a cell divides 50 to 100 times, the telomeres shorten so much that they can no longer protect the chromosome, and the cell eventually dies.

Scientists believe that such cell death is normal, even healthy. But as a healthy cell turns cancerous, a genetic mutation triggers the production of telomerase, which restores the telomeres to normal length. The restored telomeres enable the cell to divide, unchecked, thousands of times instead of the usual 50 to 100. Over time, a few cancer cells can multiply into a golf-ball-sized tumor or spread to other parts of the body.

Since researchers discovered the important role telomerase plays in most cancers in the mid-1990s, much attention has been focused on finding a way to attack them. Several methods are in various stages of development.

The University of Rochester team used RNA interference to disrupt the production of telomerase in various cancer cells including colon, skin, cervical, and lung cancer. They crafted tiny snippets of double-
'"/>

Contact: Christopher DiFrancesco
chris_difrancesco@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
14-Jul-2003


Page: 1 2

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: University Rochester scientists test new method attack cancer

(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... such as its definition, classification, application and industry ... process, and product cost structure. Production is separated ... covers upstream raw materials, equipment, downstream client survey, ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
Cached News: